Broadcast Date: October 24th, 2017
Time: 11:00 am ET, 8:00 am PT, 17:00 CET

This webinar has ended. Please check back shortly for the recording available on demand.

Cell-based immunotherapeutics have expanded the clinical drug repertoire for many diseases and provide immeasurable hope for patients who are intractable to the standard of care treatments. Emboldened by the success of cell therapies, investigators are looking for improved modalities by which to generate novel treatments, as well as enhancing existing processes to improve production efficiencies and therapy efficacy. Join us for this upcoming GEN webinar where we will discuss some of the latest tools and technologies currently being employed to enhance immunotherapy culture conditions.

Who Should Attend

  • Immunotherapy researchers
  • Cell therapy production scientists
  • Scientists working in process development and biomanufacturing
  • Translational research scientists
  • Clinical researchers

You Will Learn

  • About the latest methodologies and improvements in cell culture conditions that will streamline laboratory and manufacturing workflows
  • How various immune cells are made under good manufacturing practices (GMP) conditions
  • About the importance of closed and automated manufacturing technologies

Produced with support from:

Sponsor Logo

Panelists

John C. Bell, Ph.D.
Senior Scientist,
The Ottawa Hospital, University of Ottawa

Patrick J. Hanley, Ph.D.
Assistant Professor and Laboratory Facility Director,
Children’s National Medical Center, The George Washington University

Lior Raviv,
Vice President, Development,
Pluristem Therapeutics